Showing results (71-80 of 185) with videos related to
Sort By:
Pageof 19
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2025
Week 12 Reduction in MM-SES-CD is Predictive of Delayed Response to Upadacitinib in Crohn's diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 16, 2023
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center studyTalat Bessissow, Neeraj Narula, Christopher Ma, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 31, 2024
Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's diseaseTalat Bessissow, Neeraj Narula, Christopher Ma, et al.Digestive Diseases and Sciences|February 19, 2026
Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENTEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Journal of Crohn'S & Colitis|October 11, 2022
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction StudiesPaul Bahnam, Jurij Hanzel, Christopher Ma, et al.Inflammatory Bowel Diseases|September 25, 2025
Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Alimentary Pharmacology & Therapeutics|February 15, 2022
Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 27, 2022
Predictors of Placebo Induction Response and Remission in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Inflammatory Bowel Diseases|August 3, 2022
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's DiseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Plos One|May 28, 2020
Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysisJohan Burisch, Wolfgang Eigner, Stefan Schreiber, et al.Pageof 19